Key result
Genetic liability to smoking was strongly associated with increased risk of PAD (OR 2.13; 95% CI 1.78-2.56), CAD (OR 1.48), and large-artery stroke (OR 1.40).
Why the study?
Smoking is linked to atherosclerotic cardiovascular disease, but its relative contribution to CAD, PAD, and large-artery stroke remains less well understood.
Does genetic liability to smoking increase the risk of CAD, PAD, and large-artery stroke?
Observational
Yes
Does genetic liability to smoking increase the risk of CAD, PAD, and large-artery stroke?
Odds Ratio: 2.13 (95% CI 1.78–2.56)
p-value: p=3.6 × 10-16
Genetic liability to smoking is a strong, independent risk factor for atherosclerotic cardiovascular diseases, with the strongest association observed for peripheral artery disease.
Reinforces smoking cessation counseling; extends observational data via genetic evidence but leaves causal translation open.
Importance: Smoking is associated with atherosclerotic cardiovascular disease, but the relative contribution to each subtype (coronary artery disease [CAD], peripheral artery disease [PAD], and large-artery stroke) remains less well understood. Objective: To determine the association between genetic liability to smoking and risk of CAD, PAD, and large-artery stroke. Design, Setting, and Participants: Mendelian randomization study using summary statistics from genome-wide associations of smoking (UK Biobank; up to 462 690 individuals), CAD (Coronary Artery Disease Genome Wide Replication and Meta-analysis plus the Coronary Artery Disease Genetics Consortium; up to 60 801 cases, 123 504 controls), PAD (VA Million Veteran Program; up to 24 009 cases, 150 983 controls), and large-artery stroke (MEGASTROKE; up to 4373 cases, 406 111 controls). This study was conducted using summary statistic data from large, previously described cohorts. Review of those publications does not reveal the total recruitment dates for those cohorts. Data analyses were conducted from August 2019 to June 2020. Exposures: Genetic liability to smoking (as proxied by genetic variants associated with lifetime smoking index). Main Outcomes and Measures: Risk (odds ratios [ORs]) of CAD, PAD, and large-artery stroke. Results: Genetic liability to smoking was associated with increased risk of PAD (OR, 2.13; 95% CI, 1.78-2.56; P = 3.6 × 10-16), CAD (OR, 1.48; 95% CI, 1.25-1.75; P = 4.4 × 10-6), and stroke (OR, 1.40; 95% CI, 1.02-1.92; P = .04). Genetic liability to smoking was associated with greater risk of PAD than risk of large-artery stroke (ratio of ORs, 1.52; 95% CI, 1.05-2.19; P = .02) or CAD (ratio of ORs, 1.44; 95% CI, 1.12-1.84; P = .004). The association between genetic liability to smoking and atherosclerotic cardiovascular diseases remained independent from the effects of smoking on traditional cardiovascular risk factors. Conclusions and Relevance: In this mendelian randomization analysis of data from large studies of atherosclerotic cardiovascular diseases, genetic liability to smoking was a strong risk factor for CAD, PAD, and stroke, although the estimated association was strongest between smoking and PAD. The association between smoking and atherosclerotic cardiovascular disease was independent of traditional cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Levin et al. (2021) conducted an observational in Atherosclerotic cardiovascular diseases. Genetic liability to smoking was evaluated on Risk of peripheral artery disease (PAD) (OR 2.13, 95% CI 1.78-2.56, p=3.6 × 10-16). Genetic liability to smoking was strongly associated with increased risk of PAD (OR 2.13; 95% CI 1.78-2.56), CAD (OR 1.48), and large-artery stroke (OR 1.40).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: